Chris Stevo | SVP and Chief IR Officer |
Dr. Albert Bourla | Chairman and CEO |
Dave Denton | CFO |
Dr. Mikael Dolsten | President, Worldwide Research, Development and Medical |
Angela Hwang | Chief Commercial Officer and President, Global Biopharmaceuticals Business |
Aamir Malik | Chief Business Innovation Officer |
Dr. William Pao | Chief Development Officer |
Louise Chen | Cantor |
Terence Flynn | Morgan Stanley |
Robyn Karnauskas | Truist |
Geoff Meacham | Bank of America |
Steve Scala | Cowen |
Colin Bristow | UBS |
Trung Huynh | Credit Suisse |
Tim Anderson | Wolfe Research |
Mohit Bansal | Wells Fargo |
Chris Schott | JPMorgan |
David Risinger | SVB Securities |
Chris Shibutani | Goldman Sachs |
Carter Gould | Barclays |
Kerry Holford | Berenberg |
Andrew Baum | Citigroup |
Evan Seigerman | BMO |
Good day, everyone, and welcome to Pfizer’s Fourth Quarter 2022 Earnings Conference Call. Today’s call is being recorded.
At this time, I would like to turn the call over to Mr. Chris Stevo, Senior Vice President and Chief Investor Relations Officer. Please go ahead, sir.